- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Mays Cancer Center at UT Health San Antonio | Strategic Alliance Partners
Latest from Mays Cancer Center at UT Health San Antonio
Dr. Mesa on the Anticipated Utility of Momelotinib in Myelofibrosis
December 07, 2020
Video
Ruben A. Mesa, MD, discusses the anticipated utility of momelotinib in myelofibrosis.
Dr. Mesa on the Potential Role of Momelotinib for Myelofibrosis-Associated Anemia
December 01, 2020
Video
Ruben A. Mesa, MD, discusses the potential role of momelotinib in alleviating myelofibrosis-associated anemia.
Dr. Mesa on Management Strategies for MPNs
October 23, 2020
Video
Ruben A. Mesa, MD, discusses management strategies for patients with myeloproliferative neoplasms.
Dr. Mesa on the Rationale for the Earlier Use of Ruxolitinib in Myelofibrosis
October 16, 2020
Video
Ruben A. Mesa, MD, discusses the rationale for the earlier use of ruxolitinib in myelofibrosis.
Dr. Mesa on Remaining Challenges Faced in MPN Treatment
October 15, 2020
Video
Ruben A. Mesa, MD, discusses remaining challenges faced in the treatment of patients with myeloproliferative neoplasms.
Dr. Mesa on Emerging Therapies in Myelofibrosis
September 23, 2020
Video
Ruben A. Mesa, MD, discusses emerging therapies in myelofibrosis.
Dr. Mesa on the Emergence of JAK Inhibitors in Myelofibrosis
September 11, 2020
Video
Ruben A. Mesa, MD, discusses the emergence of JAK inhibitors in myelofibrosis.
Dr. Mesa on Current Data With Ruxolitinib and Fedratinib in Myelofibrosis
September 09, 2020
Video
Ruben A. Mesa, MD, discusses current data with ruxolitinib and fedratinib in myelofibrosis.
Dr. Mesa on Accrual Considerations in MPN Clinical Trials
August 17, 2020
Video
Ruben A. Mesa, MD, discusses accrual considerations in myeloproliferative neoplasms clinical trials.
Dr. Mesa on Developing Racially Inclusive Clinical Trials in MPNs
August 13, 2020
Video
Ruben A. Mesa, MD, discusses the importance of developing racially inclusive clinical trials in myeloproliferative neoplasms.
Dr. Mesa on Racial Disparities in MPN, MDS, and AML Clinical Trials
August 10, 2020
Video
Ruben A. Mesa, MD, discusses racial disparities in clinical trials for patients with myeloproliferative neoplasms, myelodysplastic syndrome, and acute myeloid leukemia.
Dr. Mesa on Mitigating Racial Disparities in MPN Clinical Trials
August 05, 2020
Video
Ruben A. Mesa, MD, discusses mitigating racial disparities in myeloproliferative neoplasm clinical trials.
Dr. Mesa on the Potential Utility of CAR T-Cell Therapy in MPNs
August 03, 2020
Video
Ruben A. Mesa, MD, discusses the potential utility of CAR T-cell therapy in myeloproliferative neoplasms.
Dr. Mesa on the Utility of Ruxolitinib Versus Fedratinib in Myelofibrosis
April 21, 2020
Video
Ruben Mesa, MD, discusses the use of ruxolitinib versus fedratinib in patients with myelofibrosis and baseline thrombocytopenia.
Dr. Mesa on Treatment Advancements Made in MPNs
April 16, 2020
Video
Ruben A. Mesa, MD, discusses advancements made in the treatment of patients with myeloproliferative neoplasms.
Mesa Provides Perspective on Diagnosis and Treatment in Essential Thrombocythemia
April 15, 2020
Article
Ruben A. Mesa, MD, discusses the current state of ET treatment, the challenges of diagnosing the disease, and available educational resources for healthcare providers and patients.
Dr. Mesa on Challenges in Myelofibrosis Treatment
April 08, 2020
Video
Ruben Mesa, MD, discusses remaining challenges in treating myelofibrosis.
Dr. Mesa on Investigative Therapies in Myelofibrosis
March 26, 2020
Video
Ruben Mesa, MD, discusses therapiesunder investigation in myelofibrosis.
Mesa Discusses Next Steps in Myelofibrosis
March 25, 2020
Article
Ruben Mesa, MD, discusses the latest advancements in the treatment paradigm for patients with myelofibrosis.
Dr. Mesa on Challenges With JAK Inhibitors in Myelofibrosis
March 14, 2020
Video
Ruben Mesa, MD, discusses the challenges with using JAK inhibitors in myelofibrosis.